SOX2 and melanoma: In their study, they found that high SOX2 expression is associated with worse survival and low objective response rate in patients with high PD-L1 who were treated with the anti-PD-1 monoclonal antibody, which indicates that SOX2 is an independent predictor for poor prognosis and resistance to anti-PD-1 treatment in melanoma patients with high PD-L1 levels [145].